XKRX068270
Market cap27bUSD
Jan 13, Last price
183,800.00KRW
1D
-0.70%
1Q
-8.33%
Jan 2017
71.14%
IPO
377.84%
Name
Celltrion Inc
Chart & Performance
Profile
Celltrion, Inc., together with its subsidiaries, develops and produces therapeutics based on proteins including oncology treatment drugs in South Korea. The company markets Remsima, Truxima, and Herzuma products; generic pharmaceuticals; covid-19 test kits. Its antibody biosimilar pipeline includes CT-P39 for the treatment of asthma and urticaria that is in phase 1 clinical trial; CT-P17 for the treatment of rheumatoid arthritis, psoriatic arthritis, and IBD, which is in phase 3 clinical trial; CT-P16 for the treatment of metastatic colorectal cancer and breast cancer that is in phase 3 clinical trial; CT-P41 for the treatment of osteoporosis and bone loss, which is in phase 1 clinical trial; CT-P43 for the treatment of psoriasis, crohn's disease, and ulcerative colitis that is in phase 3 clinical trial; CT-P42 for the treatment of diabetic macular edema, which is in phase 3 clinical trial; CT-P27 for the treatment of pandemic/seasonal influenza that is in phase 2 clinical trial; CT-P59 for the treatment of COVID-19, which is in phase 3 clinical trial; and CT-G20 for the treatment of Cardiomyopathy that is in phase 1 clinical trial. Celltrion, Inc. has a partnership with Inhalon Biopharma, Inc. to develop IN-006, an inhaled form of regdanvimab for treating patients with COVID-19. The company was founded in 2002 and is headquartered in Incheon, South Korea.
Valuation
Title KRW in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY |
---|---|---|---|---|---|---|---|---|---|
2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | 2015‑12 | |
Income | |||||||||
Revenues | 2,176,431,531 -4.71% | 2,283,967,480 19.48% | |||||||
Cost of revenue | 1,437,508,864 | 1,511,126,636 | |||||||
Unusual Expense (Income) | |||||||||
NOPBT | 738,922,667 | 772,840,845 | |||||||
NOPBT Margin | 33.95% | 33.84% | |||||||
Operating Taxes | 131,389,280 | 94,826,673 | |||||||
Tax Rate | 17.78% | 12.27% | |||||||
NOPAT | 607,533,387 | 678,014,172 | |||||||
Net income | 535,647,964 -0.41% | 537,835,568 -7.18% | |||||||
Dividends | (51,663,582) | (102,450,966) | |||||||
Dividend yield | 0.18% | 0.46% | |||||||
Proceeds from repurchase of equity | (911,488,389) | (270,687,025) | |||||||
BB yield | 3.17% | 1.22% | |||||||
Debt | |||||||||
Debt current | 1,783,304,274 | 637,864,075 | |||||||
Long-term debt | 123,269,151 | 160,084,002 | |||||||
Deferred revenue | 88,625,992 | 160,201,589 | |||||||
Other long-term liabilities | 5,871,728 | 7,575,837 | |||||||
Net debt | 922,215,263 | 128,952,175 | |||||||
Cash flow | |||||||||
Cash from operating activities | 537,158,606 | 863,532 | |||||||
CAPEX | (210,046,190) | (311,985,700) | |||||||
Cash from investing activities | (138,864,903) | (297,051,208) | |||||||
Cash from financing activities | (385,114,627) | (350,219,428) | |||||||
FCF | (1,541,609,128) | 155,981,652 | |||||||
Balance | |||||||||
Cash | 757,497,069 | 594,463,770 | |||||||
Long term investments | 226,861,094 | 74,532,132 | |||||||
Excess cash | 875,536,586 | 554,797,528 | |||||||
Stockholders' equity | 4,539,898,044 | 6,964,992,837 | |||||||
Invested Capital | 18,235,175,645 | 4,568,412,611 | |||||||
ROIC | 5.33% | 16.54% | |||||||
ROCE | 3.84% | 15.08% | |||||||
EV | |||||||||
Common stock shares outstanding | 142,725 | 138,319 | |||||||
Price | 201,500.00 25.55% | 160,500.00 -18.94% | |||||||
Market cap | 28,759,080,246 29.54% | 22,200,176,548 -22.96% | |||||||
EV | 29,826,406,409 | 22,463,972,993 | |||||||
EBITDA | 984,749,999 | 999,230,868 | |||||||
EV/EBITDA | 30.29 | 22.48 | |||||||
Interest | 9,665,286 | 7,507,535 | |||||||
Interest/NOPBT | 1.31% | 0.97% |